These 2 Pharmas Have Made Their Pipelines a Competitive Advantage

Alex Carchidi, The Motley Fool
·4-min read
These 2 Pharmas Have Made Their Pipelines a Competitive Advantage
These 2 Pharmas Have Made Their Pipelines a Competitive Advantage

To get the maximum return from approved drugs, many pharma companies don't stop developing their pipeline projects once they hit the market. Instead, they test their approved drugs for efficacy in treating other diseases and seek new indications to increase the size of their eligible patient populations. Similarly, some manufacturers experiment with bundling older approved drugs into new combinations to improve their efficacy, in an attempt to revitalize segments with ebbing revenue.